NCT02511886View on ClinicalTrials.gov

A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Alcohol Use Disorder
Interventions
DRUG

Arbaclofen Placarbil

Arbaclofen Placarbil

DRUG

Placebo

Placebo matched tablets

Trial Locations (1)

33334

Research Centers of America, Oakland Park

Sponsors

Lead Sponsor

Indivior Inc.
All Listed Sponsors
lead

Indivior Inc.

INDUSTRY

NCT02511886 - A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder | Biotech Hunter | Biotech Hunter